Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dendreon Gains Approval for Atlanta Manufacturing Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dendreon Gains Approval for Atlanta Manufacturing Facility

To manufacture cancer treatment Provenge

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon Corp. received approval from the FDA for its cancer immunotherapy manufacturing facility in Atlanta, GA for the production of Provenge (sipuleucel-T), a treatment for metastatic castrate resistant (hormone refractory) prostate cancer. The Atlanta facility includes 36 workstations. The company plans to bring these new workstations online in a staged approach. Along with NJ and CA facilities, Dendreon now has three facilities available to manufacture Provenge.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics